Plain-English translation of NCT07786077 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
Researchers want to understand what matters most to patients when choosing treatments for primary immune thrombocytopenia โ a condition where your immune system attacks blood cells that help with clotting. This study isn't testing a new medication; instead, it's asking people like you to complete a survey about what you value in a treatment, so doctors can better understand patient priorities.
Patients have different needs and concerns when choosing treatments for this condition. By learning what features of treatment matter most to you โ whether that's side effects, how often you take it, how well it works, or something else โ researchers can help guide better treatment decisions in the future.
You likely qualify ifโฆ
You likely don't qualify ifโฆ
You will complete a survey designed to understand your treatment preferences โ for example, what side effects concern you most, how important convenience is to you, or what outcomes matter most. The whole study takes place in two stages: first researchers will develop the survey with input from patients and doctors, then they will give the final survey to about 100 participants and analyze the results. It's a completely non-invasive study with no medications or procedures involved.
AI-generated summary from trial data ยท Aug 27, 2026 ยท Not medical advice
United States
Sponsor
Novartis Pharmaceuticals
Enrollment target
~100 participants
Started
December 2025
Primary completion
December 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in August 2026.
Reach out to the team running this trial. Response times vary โ some teams are faster than others.
Central contact
Novartis Pharmaceuticals
Novartis Pharmaceuticals
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first โ no email needed to get started.